Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Naptumomab estafenatox - Active Biotech/NeoTX Therapeutics

Drug Profile

Naptumomab estafenatox - Active Biotech/NeoTX Therapeutics

Alternative Names: ABR-217620; Anyara; NAP - Active Biotech/NeoTx Therapeutics; NTX 352; TTS CD3

Latest Information Update: 26 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Active Biotech
  • Developer Active Biotech; AstraZeneca; NeoTX Therapeutics
  • Class Antineoplastics; Drug conjugates; Fab fragments; Immunotherapies; Immunotoxins; Recombinant fusion proteins
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I/II Solid tumours
  • Phase I Oesophageal cancer
  • Suspended Pancreatic cancer; Renal cancer

Most Recent Events

  • 11 Apr 2024 NeoTX Therapeutics and Weill Medical College of Cornell University withdraw a phase I trial in Urogenital cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) prior to enrollment due to insufficient funds (NCT05894447)
  • 28 Mar 2024 Phase-I clinical trials in Oesophageal cancer (IV) (NeoTX Therapeutics pipeline, July 2024)
  • 30 Jan 2024 NeoTX Therapeutics completes a phase II trial in Non-small cell lung cancer (Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT04880863)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top